NATCO Pharma Launches Generic Pomalidomide Capsules in U.S. Market

NATCO Pharma Limited (NSE: NATCOPHARM), in partnership with Breckenridge Pharmaceutical, Inc, has announced the launch of Pomalidomide Capsules in the United States. The product is a generic version of Pomalyst®, originally developed by Celgene.

Therapeutic Indications

Pomalidomide, a thalidomide analogue, is indicated for the treatment of adult patients with multiple myeloma who have undergone at least two prior therapies, including lenalidomide and a proteasome inhibitor, and have shown disease progression.

It is also approved for treating AIDS-related Kaposi sarcoma following failure of highly active antiretroviral therapy, as well as for HIV-negative adult patients with Kaposi sarcoma.

The capsules are available in 1mg, 2mg, 3mg, and 4mg strengths and are primarily distributed through specialty pharmacies and clinics.

Market Opportunity and Exclusivity

According to industry sales data, Pomalidomide recorded estimated U.S. sales of approximately USD 3.2 billion for the 12 months ending September 2025. NATCO believes, based on information from the U.S. Food and Drug Administration (FDA), that it holds 180 days of shared exclusivity, potentially offering a competitive advantage during the initial launch phase.

Rajeev Nannapaneni, Vice Chairman and Chief Executive Office of NATCO Pharma Limited said, “We are pleased to launch Pomalidomide Capsules in the U.S., this further strengthens our oncology and specialty portfolio in the U.S. The launch highlights our commitment to our mission of making specialty medicines accessible to all the patients worldwide. We look forward to bringing more such complex and specialty products to the market in the coming years.”

NATCO Pharma Share Price Today

On March 4, 2026, NATCO Pharma share price opened at ₹956.25, touching the day’s high at ₹992.40, as of 11:02 AM on the NSE.

Also Read: Natco Pharma Share Price Jumps 11% After CDSCO Approval for Semaglutide Injection in India!

Conclusion

The U.S. launch of generic Pomalidomide marks a significant milestone for NATCO Pharma, strengthening its oncology portfolio and expanding its presence in the high-value U.S. market. With substantial market potential and a period of shared exclusivity, the launch is expected to enhance revenue opportunities while providing cost-effective treatment options to patients.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a private recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.